Gene-directed enzyme prodrug therapy (GDEPT): Choice of prodrugs

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 351-364

  Springer, C J ^a   Niculescu Duvaz, I ^a  

^a CRC Centre for Cancer Therapeutics   (United Kingdom)

Author keywords

GDEPT; gene therapy; prodrug; VDEPT

Indexed keywords

DISEASES; DRUG PRODUCTS; ENZYMES; GENES; TISSUE;

ALKYLATING AGENTS; ANTIMETABOLITES; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; GENE DIRECTED ENZYME PRODRUG THERAPY; PRODRUGS; VIRUS DIRECTED ENZYME PRODRUG THERAPY;

DRUG THERAPY;

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ACICLOVIR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOPHOSPHAMIDE; DNA; ENZYME; FIALURIDINE; FLUCYTOSINE; GANCICLOVIR; IFOSFAMIDE; NITROREDUCTASE; PRODRUG; PURINE NUCLEOSIDE;

CANCER CHEMOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; DRUG DESIGN; GENE TARGETING; GENE THERAPY; HUMAN; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0030589523     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00449-8     Document Type: Review

References (48)

1. [1] Zhang, W.W., Fujiwara, T., Grimm, E.A. and Roth, J.A. (1995) Advances in cancer gene theraphy. Adv. Pharmacol. 12, 289-341.
2. [2] Huber, B.E., Austin, H.A., Richards, C.A., Davis, S.T. and Good, S.S. (1994) Metabolism of 5-fluorocytidine to 5-fluorouracil in human cotorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91, 8302-8306.
3. [3] Huber, B.A., Richards, C.A. and Krenitsky, T.A. (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88, 8039-8043.
4. [4] Moolten, F.L. (1986) Tumor chemosensitivity conferred by inserted Herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
5. [5] Borelli, E., Heyman, R., Hsi, M. and Evans, R.M. (1988) Targeting of an inducible toxic phenotype in animal cell. Proc. Natl. Acad. Sci. USA 85, 7572-7576.
6. [6] Moolten, F.L. and Wells, J.M. (1990) Curability of tumors bearing Herpes virus thymidine kinase genes transferred by retroviral vectors, J. Natl. Cancer Inst. 82, 297-300.
7. [7] Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J.L. and Klatzmann, D. (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90, 7024-7028.
8. [8] Culver, K.W., Ram, Z., Wallbridge, S., Oldfield, H.E.H. and Blaese, M.R. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
9. [9] Oldfield, E.H., Ram, Z., Culver, K.W., Blaese, R.M. and DeVroom, H.L. (1993) Gene therapy for the treatment of bram tumors using intra-tumoral transduction with thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
10. [10] Barba, D., Hardin, J., Ray, J. and Gage, F.H. (1993) Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729-735.
11. [11] Barba, D., Hardin, J., Sadelain, M. and Gage, F.H. (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348-4352.
12. [12] Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. and Woo, S.L.C. (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91, 3054-3057.
13. [13] Vile, R.G. and Hart, I.R. (1993) Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53, 3860-3864.
14. [14] Vile, R.G. and Hart, I.R. (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53, 962-967.
15. [15] Mullen, C.A., Kilstrup, M. and Blaese, R.M. (1992) Transfer of the bacterial gene for cytosine deaminase to a mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89, 33-37.
16. [16] Mullen, C.A., Coale, M.M., Lowe, R. and Blaese, R.M. (1994) Tumor expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 54, 1503-1506.
17. [17] Huber, B.E., Austin, E.A., Good, V.C., Knick, V.C., Tibbels, S. and Richards, C.A. (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53, 4619-4626.
18. [18] Harris, J.D., Gutierrez, A.A., Hurst, H.C., Sikora, K. and Lemoine, N.R. (1994) Gene therapy for cancer using tumorspecific prodrug activation. Gene Ther. 1, 1-6.
19. [19] Austin, E.A. and Huber, B.E. (1993) A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43, 380-387.
20. [20] Chen, L. and Waxman, D.J. (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589.
21. [21] Bridgewater, G., Springer, C.J., Knox, R., Minton, N., Michael, P. and Collins, M. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370.
22. [22] Dynan, W.S. and Tjian, R. (1985) Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins. Nature 316, 774-778.
23. [23] Elion, G.B. (1980) The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzymes Regul. 18, 53-66.
24. [24] Allaudeen, H.S., Descamps, J., Sehgal, R.K. and Fox, J.J. (1982) Selective inhibition of DNA replication in herpes simplex virus infected cells by 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine. J. Biol. Chem. 257. 11879-11882.
25. [25] Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. and Oldfield, E.H. (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
26. [26] Vile, R., Miller, N., Chernayovsky, Y. and Hart, I. (1994) A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1, 307-316.
27. [27] Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S. and Kishimoto, T. (1994) Gene therapy for carcinoembryonic antigen-producing cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54, 5258-5261.
28. [28] Manome, Y., Abe, M., Hagen, M.F., Fine, H.A. and Kufe, D.W. (1994) Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer. Cancer Res. 54, 5408-5413.
29. [29] O'Malley Jr., B.W., Chen, S.H., Schwartz, M.R. and Woo, S.L.C. (1995) Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55, 1080-1085.
30. [30] MacCoss, M., Robins, M.J. (1990) In: D.E.V. Wilman (Ed.), Chemistry of Antitumour Agents, Chapman & Hall, London, pp. 261-298.
31. [31] Martin, D.S. (1987) In: G. Powis and R.A. Prough (Eds.), Metabolism and Action of Anti-Cancer Drugs. Taylor & Francis, London, pp. 91-140.
32. [32] Sladek, N.B. (1987) In: G. Powis and R.A. Prough (Eds.). Metabolism and Action of Anti-Cancer Drugs. Taylor & Francis, London, pp. 48-89.
33. [33] Bielicki, L., Voelcker, G. and Hohorst, H.J. (1984) Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3′.5′-exonuclease. J. Cancer Res. Clin. Oncol. 107, 195-198.
34. [34] Connors, T.A., Cox, P.J., Farmer, P.B., Foster, A.B., Gilsenan, A.M. and Jarman, M. (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem. Pharmacol. 23, 115-129.
35. [35] Chang, T.K.H., Weber, G.F., Crespi, C.L. and Waxman, D.J. (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637.
36. [36] Halpern, J., Jaw, J.Y., Cornfield, L.J., Balfour, C. and Mash, E. (1989) Selective inactivation of rat liver cytochromes P450 by 21-chlorinated steroids. Drug Metab. Dispos. 17, 26-31.
37. [37] Correia, M.A., Yao, K., Wrighton, S.A., Waxman, D.J. and Rettie, A.E. (1992) Differential apoprotem loss of rat liver cytochromes P450 after their inactivation by 3.5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanism. Arch. Biochem. Biophys. 294, 493-503.
38. [38] Khan, A.C. and Ross, W.C.J. (1967) Tumour growth inhibitory nitrophenylaziridines and related compounds: structure activity relationships. Chem.-Biol. Interact. 1, 27-47.
39. [39] Knox, R.J., Boland, M.P., Friedlos, F., Coles, B., Southan, C. and Roberts, J.J. (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2.4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 44, 2297-2301.
40. [40] Knox, R.J., Friedlos, F., Sherwood, R.F., Melton, R.G. and Anlezark, G.M. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT-diaphorase. Biochem. Pharmacol. 44, 2297-2301.
41. [41] Boland, M.P., Knox, R.J. and Roberts, J.J. (1991) The differences in kinetics of rat and human DT-diaphorase result in in a differential sensitivity of cells lines to CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide. Biochem. Pharmacol. 41, 867-875.
42. [42] Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.S. and Abraham, G.N. (1993) The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
43. [43] Goldberg, G. and Bertram, J.S. (1994) Correspondence re Ram et al.: in situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88 and 54, 3947-3948, 1993.
44. [43] Goldberg, G. and Bertram, J.S. (1994) Correspondence re Ram et al.: in situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88 and 54, 3947-3948, 1993.
45. [44] Dagher, S.F., Conrad, S.E., Werner, E.A. and Patterson, R.J. (1992) Phenotypic conversion of TK-deficient cells following electroporation of functional TK enzyme. Exp. Cell Res. 198, 36-42.
46. [45] Golumbek, P.T., Hamzeh, P.M., Jaffee, E.M., Levitsky, H., Lietman, P.S. and Pardoll, D.M. (1992) Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumour cell vaccines. J. Immunother. 12, 224-230.
47. [46] Teicher, B.A. and Frei III, E. (1988) Development of alkylating agent resistant human tumor cell lines. Cancer Chemother. Pharmacol. 21, 292-298.
48. [47] Frei, E., Teicher, B.A. and Holden, S.A. (1988) Preclinical studies and and clinical correlation of the effect of alkylating drugs. Cancer Res. 48, 6417.